Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients with psoriatic arthritis (PsA) ...

Around a quarter of people with psoriasis eventually develop psoriatic arthritis – often a decade or more after skin symptoms. A skin biopsy is rarely needed to diagnose psoriasis in white patients, ...

In addition to psoriatic arthritis, SIT-047 also holds potential across a range of autoimmune conditions where MTHFD2 is strongly upregulated, including rheumatoid arthritis, lupus, Crohn’s ...

Treatment for psoriatic arthritis has evolved significantly in recent years, offering new hope for patients. The goals of therapy include reducing inflammation, relieving pain, preventing joint ...

With psoriatic arthritis, I discuss the role of obesity, diabetes, and depression or anxiety in PsA. I also try to assess if they have chronic pain syndrome, and if that's occurring with or ...

9. Other autoimmune conditions In addition to other symptoms, many autoimmune conditions, such as arthritis, lupus, and diabetes, can also cause poor or insufficient tear production.

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints at 16 weeks, according to late-breaking data presented at the American ...

Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and joint pain, but excess fatigue is also a symptom for at least 50% of people with PsA. Fatigue from PsA might be mild ...

Immune checkpoint inhibitor (ICI) use is associated with a higher risk for rheumatoid arthritis (RA) but lower risks for systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), compared with ...

The study population had a mean PsA duration of 5-6 years, and 85-90% had received no prior biologic therapy. Tender joint count averaged 15-17 across the three groups, and swollen joint count ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in psoriatic arthritis (PsA), the company has presented detailed data from ...